Your browser doesn't support javascript.
loading
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak, Eunice L; Ahronian, Leanne G; Siravegna, Giulia; Mussolin, Benedetta; Borger, Darrell R; Godfrey, Jason T; Jessop, Nicholas A; Clark, Jeffrey W; Blaszkowsky, Lawrence S; Ryan, David P; Lennerz, Jochen K; Iafrate, A John; Bardelli, Alberto; Hong, Theodore S; Corcoran, Ryan B.
Afiliación
  • Kwak EL; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. rbcorcoran@partners.org ekwak@partners.org.
  • Ahronian LG; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Siravegna G; Department of Oncology, University of Torino, Torino, Italy. Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Mussolin B; Department of Oncology, University of Torino, Torino, Italy. Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Godfrey JT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Clark JW; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Blaszkowsky LS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Ryan DP; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Lennerz JK; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Iafrate AJ; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Bardelli A; Department of Oncology, University of Torino, Torino, Italy. Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Hong TS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Corcoran RB; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. rbcorcoran@partners.org ekwak@partners.org.
Cancer Discov ; 5(12): 1271-81, 2015 12.
Article en En | MEDLINE | ID: mdl-26432108
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Amplificación de Genes / Heterogeneidad Genética / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-met Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2015 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Amplificación de Genes / Heterogeneidad Genética / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-met Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2015 Tipo del documento: Article